The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy

R. A. Abrams, A. S. Lichter, R. H. Bromer, J. D. Minna, M. H. Cohen, A. B. Deisseroth

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Using circulating granulocyte‐monocyte precursor colony‐forming units in culture (CFUc) numbers as a probe along with standard blood count (CBC), the authors have quantitatively examined the hematopoietic toxicity of conventionally fractionated radiation therapy (RT) when combined with concurrent systemic chemotherapy or when used alone. Among 20 patients with limited stage small cell lung cancer receiving systemic chemotherapy with cyclophosphamide, CCNU, and methotrexate, the addition of involved field chest RT resulted in increased hematopoietic toxicity as judged by increased need for platelet transfusion (P < 0.05) and decreased frequency of measurable CFUc (P < 0.04). Among 22 patients receiving regional radiotherapy alone consistent hematopoietic toxicity was also observed. This toxicity, although generally of only mild to moderate clinical significance, was detected earlier and to a greater degree in patients who required radiation to larger treatment volumes, who had significant amounts of bone marrow in the port, and who had a high percentage of cardiac output flowing through the port. These data suggest that the hematopoietic toxicity of regional radiotherapy may be additive to that of concurrent systemic chemotherapy and may occur more promptly and to a greater degree when treatment volumes are larger or incorporate increased amounts of marrow volume or cardiac output.

Original languageEnglish (US)
Pages (from-to)1429-1435
Number of pages7
JournalCancer
Volume55
Issue number7
DOIs
StatePublished - Apr 1 1985

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The hematopoietic toxicity of regional radiation therapy. Correlations for combined modality therapy with systemic chemotherapy'. Together they form a unique fingerprint.

Cite this